CannabisNewsWire
Editorial Coverage: In a landmark
announcement, the U.S. Food and Drug Administration (FDA)
recently approved a drug derived from pure cannabidiol (CBD),
Epidiolex, to treat seizures associated with certain forms of
severe epilepsy, setting the stage for huge changes in the world of
cannabidiol (CBD).
- FDA approval of a cannabis-based drug represents seismic
political, legal and economic shifts
- Approval likely will lead to more clinical research and further
validation of CBD therapeutic efficacy
- CBD market projected to explode to more than $2 billion in two
years with 39 percent CAGR
What’s most transformative about this drug approval is that this
is the first time the FDA — the governmental arbiter of safe and
effective medicine in the United States — has approved any
substance derived from the cannabis sativa plant and validated
certain therapeutic benefits of cannabidiol. The FDA is, to some
extent, endorsing what has been anecdotally accepted by the masses
for millennia.
CBD, a non-psychoactive cannabinoid that can be extracted from
the industrial hemp plant, is understandably generating worldwide
interest from both the scientific and investment communities. A
large part of CBD’s mass appeal is that it’s believed to aid with a
broad range of wellness concerns. CBD is known to interact with the
human endocannabinoid system, which is found throughout the body’s
nervous system, organs, connective tissues, glands and immune
system. Research indicates CBD may have the potential to treat a
wide range of conditions such as anxiety,
high blood pressure, skin issues and chronic pain. It’s
being researched to treat Alzheimer’s, and one study even suggests
CBD might be a useful addition when given with conventional
antipsychotic medications in the treatment of
schizophrenia.
Continued rigorous clinical research is being conducted to
further confirm all the potential therapeutic benefits that may be
found in this cannabinoid extract. In the meantime, the mass appeal
of CBD remains unabated, and the market for CBD products continues
to grow at an astounding rate. Committed to the legal hemp-derived
CBD market, Marijuana Company of America, Inc. (OTC: MCOA)
(MCOA
Profile) provides consumers with pure, hemp
plant-based CBD nutritional products through its global hempSMART™
brand and has initiated broad-ranging, innovative cultivation
programs for legal, high-quality hemp. Others vying for position in
the burgeoning CBD space include Isodiol International,
Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F), CV
Sciences, Inc. (OTC: CVSI), PotNetwork Holdings,
Inc. (OTC: POTN) and Medical Marijuana, Inc. (OTC:
MJNA).
The Boom Has Just Begun
Three years ago, in 2015, the hemp-derived CBD market racked up
$90 million in sales. Last year that number reached $190 million in
sales — and the boom has just begun. The Hemp
Business Journal projects $2.1 billion in total CBD sales by
2020 and estimates that $450 million of that will come from
hemp-based sources. The explosive demand projections are attributed
to an increased public awareness of the wide-ranging potential
health benefits of hemp CBD oil and advancements in cultivation,
plus the convenience and reach of online retailing — all of which
contribute to a global CBD oil market expected to grow at an
eye-popping CAGR of 39.19 percent through
2021.
Hemp Focus
With an overarching focus on the cultivation, development and
distribution of legal industrial hemp-derived products, Marijuana Company of America (OTC:
MCOA) aims to capture an outsized share of growing
worldwide demand. Pure hemp-based consumer nutritional products are
at the core of this demand, and the company has developed a
portfolio of ancillary hemp-centric businesses to vertically
integrate hemp production and sales. Cultivation of high-quality
hemp from portfolio companies feeds MCOA’s proprietary CBD-based
formulations, dovetailing to produce the finest quality nutritional
supplements on the market.
The unique company vision emanates from Donald Steinberg, MCOA’s
CEO. A cannabis industry pioneer, he founded the first
cannabinoid-centric company to trade on a U.S. stock market. His
vast knowledge and industry experience give MCOA unparalleled
insights into the machinations of the CBD markets and the vision to
capitalize on industry opportunities in a market projected to
exceed $2 billion in the coming years. In keeping with this
ambitious strategy, Steinberg and his partner, Charlie Larsen,
formed Marijuana Company of America as well its sister company,
Canadian-based Global Hemp Group, Inc. (OTC: GBHPF), which is
focused on the legal cultivation and processing of industrial hemp.
MCOA continues to build an impressive portfolio of synergistic
companies across the hemp spectrum. From farm to finished products,
MCOA’s socially conscious strategy is to capitalize at each profit
point and establish a significant footprint at multiple inflection
points across the entire hemp value chain.
Hemp-Based Nutritionals
MCOA has worked to create a recognized and respected hempSMART
product line that contains levels of clinically researched
ingredients designed to exceed consumer expectations and support
the body’s natural endocannabinoid system. To serve
health-conscious consumers, hempSMART includes an array of
proprietary nutritional products.
- hempSMART Brain is a patent-pending formulation designed for
optimal brain function support.
- hempSMART Drops offer the highest concentration and potency of
full-spectrum bioavailable CBD.
- hempSMART Pain Capsules contain a blend of premium CBD and
botanical supplements.
- hempSMART Pain Cream is a proprietary formulation for relief
from muscle and joint pain.
- hempSMART Full Spectrum Pet Drops is a unique nutritional
supplement designed for furry family members.
- hempSMART Face is a topical face moisturizer that combines CBD
oil with ayurvedic herbs and botanicals.
MCOA’s hempSMART goes through an exacting CO2 extraction process
to ensure the highest quality in the company’s natural wellness
product line. By combining these pure industrial hemp-based
cannabinoids with some of nature’s most effective wellness
ingredients, MCOA’s hempSMART products are poised to deliver
optimally formulated wellness products to health-conscious
consumers.
In a forward-thinking plan to expand retail distribution and
capitalize on impulse buys in high-traffic stores, MCOA took a 25
percent equity stake in BeniHemp-branded CBD products. BeniHemp
health-focused products include topicals, tinctures and edibles
packaged in one-day, two-day and thirty-day supplies widely
distributed to convenience stores, smoke shops, gas stations and
small retail outlets.
A Growing Portfolio
In addition to the hempSMART and BeniHemp consumer products
lines, MCOA continues to strategically assemble synergistic
portfolio companies. In a joint venture with sister company Global
Hemp Group, MCOA launched a 125-acre industrial hemp cultivation
project in northeast New Brunswick, Canada. The project targets the
promotion of hemp farming while providing year-round jobs in crop
and finished product processing.
Also in conjunction with Global Hemp Group, MCOA is developing
Covered Bridge Acres, an innovative high-yielding CBD hemp
cultivation project in Oregon. The project utilizes both
traditional outdoor cultivation and what will ultimately become
more than 19,000 square feet of indoor greenhouses, which are
slated to eventually supply the raw oil needed for the hempSMART
CBD product line.
MCOA also took a 15 percent equity stake in MoneyTrac
Technology, Inc., a subsidiary of Global Payout, Inc. (OTC: GOHE).
MCOA made this investment to help establish and market MoneyTrac
Technology as an alternative banking solution for the cannabis
industry.
Others Vying for Position
Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF)
(FSE: LB6A.F) grows and harvests hemp on an industrial
scale then processes it to extract the cannabidiol for
distribution. The company commercializes pharmaceutical-grade
cannabinoids, micro-encapsulations and nanotechnology for
consumable and topical skin care products. Isodiol has announced
plans to develop additional over-the-counter and pharmaceutical
drugs, expand its phytoceutical portfolio and expand into Latin
America, Asia and Europe.
CV Sciences, Inc. (OTCQB: CVSI) operates in two
business segments. The company’s drug development division develops
and commercializes novel therapeutics utilizing synthetic CBD. Its
consumer product division manufactures, markets and sells
plant-based CBD products to a range of market sectors. The company
is also developing and pursuing FDA approval for drugs with
specific indications utilizing cannabidiol as the active
pharmaceutical ingredient.
Founded by MCOA CEO Donald Steinberg in 2009, Medical
Marijuana, Inc. (OTC: MJNA) was the first U.S.-traded CBD
company. The company develops, distributes and sells hemp oil that
contains naturally occurring cannabinoids, including CBD. The
company sells its hemp-derived CBD products through a variety of
distribution subsidiaries. The company was among the first to bring
hemp-based CBD oil products to market in the United States and the
first to receive federal government import approvals in Mexico,
Paraguay and Brazil.
PotNetwork Holdings, Inc. (OTC: POTN) is a
publicly traded company that acts as a holding company for its
subsidiaries, First Capital Venture Co.; Diamond CBD, Inc.; and
Sunrise Auto Mall, Inc. Diamond CBD focuses on the research,
development and multinational marketing of hemp extracts that
contain a broad range of cannabinoids and natural hemp derivatives.
Diamond CBD’s team consists of hemp industry professionals,
chemists, doctors and scientists — all working together to produce
CBD oils.
Seismic Shift
Modern science has begun to substantiate both the anecdotal
history and the therapeutic efficacy of cannabidiol. The FDA’s
recent approval of a cannabis-based drug represents a seismic shift
and is further indication of the enormous curative potential that
may be found in CBD. As more scientific validations ensue, the
market for CBD products could easily exceed expectations, and
well-positioned companies in the space could outperform the
market.
For more information on Marijuana Company of America, visit
Marijuana
Company of America, Inc. (OTC: MCOA)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize
corporate news and information, (3) enhanced press release
services, (4) social media distribution and optimization services,
and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with
an extensive team of contributing journalists and writers, CNW is
uniquely positioned to best serve private and public companies that
desire to reach a wide audience of investors, consumers,
journalists and the general public. CNW has an ever-growing
distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information
in today’s market, CNW brings its clients unparalleled visibility,
recognition and brand awareness. CNW is where news, content and
information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and
or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Isodiol (CE) (USOTC:ISOLF)
Historical Stock Chart
From Nov 2024 to Dec 2024
Isodiol (CE) (USOTC:ISOLF)
Historical Stock Chart
From Dec 2023 to Dec 2024
